Subscribe to Newsletter
Business & Regulation Business Practice, Technology and Equipment, Digital Technologies

Finding the True Meaning of Disruption

Disruptive is a term that is overused in the life science industry. It’s often applied to marginal technological upgrades or even adapting a tried and true technology to a new application. That said, the current transformation in our industry is both exciting and unknown – and, by definition, disruptive.

Much like the scientific revolution currently being fueled by novel modalities, such as RNA, cell therapy and gene therapy, we are also seeing swift technological advancements. Pharma 4.0 is a complex ecosystem of tools, systems, and technologies that will amplify the industry’s capabilities to a degree nearing science fiction. The age of lights-out, cloud-based, fully automated, and self-learning facilities is entering the biopharma industry, and progressing at a rapid pace.

As an industry, we must prepare for the profound changes the next two decades will bring in the form of curative therapies being manufactured in factories and processes that will have little resemblance to the ones we know today. Automation will help us get there. But it is our responsibility to harness the power of this revolution to make cures and therapies accessible to patients around the globe.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Noel Maestre

Noel Maestre is Vice President, Life Sciences at CRB

Related White Papers
Nitrosamines Risk Mitigation: The critical role of excipients and supplier qualification

| Contributed by DFE Pharma GmbH & Co. KG

Performance validation of ScatterX78 against NIST reference materials

| Contributed by Malvern Panalytical

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine